TWiV 1016: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses surveillance to track progress toward poliomyelitis eradication, genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3, evaluation of Oseltamivir used to prevent hospitalization in outpatients with Influenza, viral emissions into the air and environment after SARS-CoV-2 human challenge, has COVID-19 threatened routine childhood vaccination, successful treatment of persistent symptomatic COVID-19 infection with extended duration Nirmatrelvir/Ritonavir, anemia as a risk factor for disease progression in patients admitted for COVID-19, impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome, post-COVID condition in patients with inflammatory rheumatic diseases, outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months, metformin reduces SARS-CoV-2 in a Phase 3 randomized placebo controlled clinical trial, persistent serum protein signatures define an inflammatory subcategory of long COVID, and the relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome.
Subscribe (free):\xa0Apple Podcasts,\xa0Google Podcasts,\xa0RSS,\xa0email
Become a\xa0patron\xa0of\xa0TWiV!
Links for this episode- Surveillance\xa0to track progress toward poliomyelitis eradication (CDC)
- Genetic stabilization of\xa0attenuated oral vaccines\xa0against poliovirus types 1 and 3 (Nature)
- Evaluation of Oseltamivir to prevent hospitalization in outpatients with\xa0Influenza\xa0(JAMA)
- Viral emissions\xa0into air and environment after SARS-CoV-2 human challenge (The Lancet)
- Has COVID-19 threatened\xa0routine childhood vaccination\xa0(Health Affairs)
- Successful treatment\xa0of COVID-19 with extended duration Nirmatrelvir/Ritonavir (OFID)
- Anemia as a risk factor for disease progression in patients admitted for\xa0COVID-19\xa0(Nature)
- Impact of fatigue\xa0as the determinant of functional limitations among patients with post-COVID-19 syndrome (BMJ)
- Post-COVID condition in patients with\xa0inflammatory rheumatic diseases\xa0(The Lancet)
- Outpatient treatment\xa0of COVID-19 and incidence of post-COVID-19 condition (The Lancet)
- Metformin reduces\xa0SARS-CoV-2\xa0in a Phase 3 placebo controlled clinical trial (MedRxiv)
- Persistent serum protein define an inflammatory subcategory of\xa0long COVID\xa0(Nature)
- Relevance\xa0of pacing strategies in managing symptoms of post-COVID-19 syndrome (JTM)
- Contribute to our\xa0FIMRC fundraiser at PWB
- Letters read\xa0on TWiV 1016
- Dr. Griffin\u2019s COVID treatment summary (pdf)
- Timestamps by\xa0Jolene. Thanks!
Intro music is by\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv